Among the JAKs, JAK3 is the most important target for the treatment of inflammatory diseases because its inhibition showed the utmost immunosuppression. Many JAK3 inhibitors are already available but most of them showed acquired drug resistance or objectionable side effects. To prevent inflammatory diseases, novel and superior drugs are needed. The drug repositioning is an alternate process that can be used as a fast-track approach. Drugs already approved by regulatory agencies have well-known pharmacokinetics and safety profile. When a new therapeutic activity has been identified, the entities can be rapidly advanced into clinical trials. To identify new promising lead molecules, we have selected 1150 approved drugs for their potential to be repurposed for inflammatory diseases. The library of approved drugs was obtained from zinc data base and JAK3 (PDB ID: 3LXK) was retrieved from protein data bank and used for molecular docking simulation and protein-ligand interaction analysis. The virtual screening of full library of drugs by AutoDock Vina version PyRx 0.8 and selected 100 drug molecules and further filtered through click-1 docking software. The binding affinity of top 8 drugs ranges between –10.3 to –7.8 kcal/mole. The threshold binding affinity of fluspirilene for JAK3 was –10.3 kcal/mole was repurposed to be promising drug candidate for inflammatory diseases. The results showed that fluspirilene has best docking interaction with JAK3 (PDB ID: 3LXK) and molecular dynamics simulation was also carried out to investigate structural conformations and to explore the key amino acids in the interaction between target and ligands. In conclusion, fluspirilene could be one of the alternative drugs for the treatment of inflammatory diseases.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
Levy, D.E., Kessler, D.S., Pine, R., Reich, N., and Darnell, J.E., Jr., Genes Dev., 1988, vol. 2, no. 4, pp. 383–393. https://doi.org/10.1101/gad.2.4.383
Schindler, C., Shuai, K., Prezioso, V.R., and Darnell, J.E., Jr., Science, 1992, vol. 257, pp. 809–813. https://doi.org/10.1126/science.149640
Stark, G.R. and Darnell, J.E., Jr., Immunity, 2012, vol. 36, no. 4, pp. 503–514. https://doi.org/10.1016/j.immuni.2012.03.013
O’Shea, J.J., Gadina, M., and Schreiber, R.D., Cell, 2002, vol. 109, pp. S121–S131. https://doi.org/10.1016/s0092-8674(02)00701-8
Ghoreschi, K., Laurence, A., and O’Shea, J.J., Immunol Rev., 2009, vol. 228, no. 1, pp. 273–287. https://doi.org/10.1111/j.1600-065X.2008.00754.x
Liongue, C., O’Sullivan, L.A., Trengove, M.C., and Ward, A.C., PLoS One, 2012, vol. 7, no. 3, p. e32777. https://doi.org/10.1371/journal.pone.0032777
Clark, J.D., Flanagan, M.E., and Telliez, J.B., J. Med. Chem., 2014, vol. 57, no. 12, pp. 5023–5038. https://doi.org/10.1021/jm401490p
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., and Schwartz, D.M., Curr. Future Prosp., 2017, vol. 77, no. 5, pp. 521–546. https://doi.org/10.1007/s40265-017-0701-9
Recio, C., Guerra, B., Guerra-Rodríguez, M., Aranda-Tabío, H., Martín-Rodríguez, P., de Mirecki-FGarrido, M., Brito-Casillas, Y., García-Castellano, J.M., Estévez-Braun, A., and Fernández-Pérez, L., Oncogene, 2019, vol. 38, no. 24, pp. 4657–4668. https://doi.org/10.1038/s41388-019-0752-3
Waickman, A.T., Park, J.Y., and Park, J.H., Cell Mol. Life Sci., 2016, vol. 73, pp. 253–269. https://doi.org/10.1007/s00018-015-2062-4
O’Shea, J.J., Schwartz, D.M., Villarino, A.V., Gadina, M., McInnes, I.B, and Laurence, A., Annu. Rev. Med., 2015, vol. 66 pp. 311–328. https://doi.org/10.1146/annurev-med-051113-024537
O’Shea, J.J., Kontzias, A., Yamaoka, K., Tanaka, Y., and Laurence, A., Ann. Rheum. Dis., 2013, vol. 72, pp. ii111–ii115. https://doi.org/10.1136/annrheumdis-2012-202576
Vyas, D., O’Dell, K.M., Bandy, J.L., and Boyce, E.G., Ann. Pharm., 2013, vol. 47, no. 11, pp. 1524–1531. https://doi.org/10.1177/1060028013512790
Winthrop, K.L., Nat. Rev. Rheumatol., 2017, vol. 13, no. 4, pp. 234–243. https://doi.org/10.1038/nrrheum.2017.23
Hughes, J.P., Rees, S., Kalindjian, S.B., and Philpott, K.L., Br. J. Pharmacol., 2011, vol. 162, no. 6, pp. 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x
Royle, K.E., del Val, I.J., and Kontoravdi, C., Drug Dis. Today, 2013, vol. 18, no. 23–24, pp. 1250–1255. https://doi.org/10.1016/j.drudis.2013.07.002
DNDi Target Product Profiles. https://dndi.org/diseases/. June 4, 2022.
MMV Target Product Profiles. https://www.mmv.org/ learning-resources-scientists. June 4, 2022.
Weisman, J.L., Liou, A.P., Shelat, A.A., Cohen, F.E., Guy, R.K., and DeRisi, J.L., Chem. Biol. Drug Des., 2006, vol. 67, no. 6, pp. 409–416. https://doi.org/10.1111/j.1747-0285.2006.00391.x
Chong, C.R. and Sullivan, D.J., Jr., Nature, 2007, vol. 448, no. 7154, pp. 645–646. https://doi.org/10.1038/448645a
Vilar, S., Cozza, G., and Moro, S., Curr. Top. Med. Chem., 2008, vol. 8, no. 18, pp. 1555–1572. https://doi.org/10.2174/156802608786786624
Shukla, P., Khandelwal, R., Sharma, D., Dhar, A., Nayarisseri, A., and Singh, S.K., Bioinformation, 2019, vol. 15, no. 2, pp. 121–130. https://doi.org/10.6026/97320630015121
Vargas, J.A.R., Lopez, A.G., Piñol, M.C., and Froeyen, M., J. Appl. Pharm. Sci., 2018, vol. 8, no. 3, pp. 14–022. https://doi.org/10.7324/JAPS.2018.8303
Pandey, P., Prasad, K., Prakash, A., and Kumar, V., J. Mol. Med., 2020, vol. 98, pp. 1659–1673. https://doi.org/10.1007/s00109-020-01980-1
Jain, D., Udhwani, T., Sharma, S., Gandhe, A., Reddy, P.B., Nayarisseri, A., and Singh, S.K., Bioinformation, 2019, vol. 15, no. 2, pp. 68–78. https://doi.org/10.6026/97320630015068
Luo, W., Li, Y.X., Jiang, L.J., Chen, Q., Wang, T., and Ye, D.W., Trends Pharmacol. Sci., 2020, vol. 41, no. 8, pp. 531–543. https://doi.org/10.1016/j.tips.2020.06.007
Kudlacz, E., Sawyer, P., Conklyn, M., McCurdy, S., Brissette, W., Flanagan, M., and Changelian, P., Am. J. Transplant., 2004, vol. 4, no. 1, pp. 51–57. https://doi.org/10.1046/j.1600-6143.2003.00281.x
Ghoreschi, B.P.K., Jesson, M.I., Li, X., Lee, J.L., Ghosh, S., Alsup, J.W., Warner, J.D., Tanaka, M., Steward-Tharp, S.M., Gadina, M., Thomas, C.J., Minnerly, J.C., Storer, C.E., LaBranche, Radi, Z.A., Dowty, M.E., Head, R.D., Meyer, D.M., Kishore, N., and O’Shea, J.J., J. Immunol., 2011, vol. 186, no. 7, pp. 4234–4243. https://doi.org/10.4049/jimmunol.1003668
Milici, A.J., Kudlacz, E.M., Audoly, L., Zwillich, S., and Changelian, P., Arthritis Res. Ther., 2008, vol. 10, article no. R14. https://doi.org/10.1186/ar2365
Irwin, J.J. and Shoichet, B.K., J. Chem. Inf. Mod., 2005, vol. 45, no. 1, pp. 177–182. https://doi.org/10.1021/ci049714
Farhadi, T., Fakharian, A., and Ovchinnikov, R.S., Interdiscip. Sci., 2018, vol. 10, no. 4, pp. 694–703. https://doi.org/10.1007/s12539-017-0222-y
Singh, S. and Florez, H., F1000Res., 2020, vol. 9, p. 502. https://doi.org/10.12688/f1000research.24218.1
The authors gratefully acknowledge the R&D wing of Integral University, Lucknow, for providing necessary facilities and communication number IU/R&D/2021-MCN0001128.
COMPLIANCE WITH ETHICAL STANDARDS
This article does not involve any animal studies.
Conflict of Interest
The authors declare that they have no conflicts of interest.
About this article
Cite this article
Sheikh, S.Y., Hassan, F., Khan, M.F. et al. Drug Repurposing to Discover Novel Anti-Inflammatory Agents Inhibiting JAK3/STAT Signaling. Russ J Bioorg Chem 48, 958–975 (2022). https://doi.org/10.1134/S106816202205020X